Left Atrial Appendage Occlusion for Stroke Prevention

Current Problems in Cardiology

Volumn 37, Issue 10, 2012, Pages 405-441

  Alli, Oluseun ^a   Holmes, David R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DABIGATRAN; PLACEBO; WARFARIN;

ACCURACY; ANATOMICAL VARIATION; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR EQUIPMENT; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXCISION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART LEFT ATRIUM; HEART PERFORMANCE; HEART VALVE SURGERY; HUMAN; INTRACARDIAC ECHOCARDIOGRAPHY; LIGATION; NONHUMAN; PREDICTION; PREVENTION STUDY; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; STROKE; SURGICAL APPROACH; SURGICAL STAPLING; THREE DIMENSIONAL ECHOCARDIOGRAPHY; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT PLANNING; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84866618643     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2012.06.001     Document Type: Article

References (102)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001, 285:2370-2375.
2. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
4. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.
5. Fatkin D., Kelly R., Feneley M.P. Left atrial appendage blood velocity and thromboembolic risk in patients with atrial fibrillation. J Am Coll Cardiol 1994, 24:1429-1430.
6. Madden J.L. Resection of the left auricular appendage. JAMA 1949, 140:769-772.
7. Bailey C.P., et al. Commissurotomy for mitral stenosis technique for prevention of cerebral complications. JAMA 1952, 149:1085-1091.
8. Belcher J.R., Somerville W. Systemic embolism and left auricular thrombosis in relation to mitral stenosis. Br Med J 1955, 2:1000-1003.
9. Johnson W.D., Ganjoo A.K., Stone C.D., et al. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000, 17:718-722.
10. Ernst G., Stöllberger C., Abzieher F., et al. Morphology of the left atrial appendage. Anat Rec 1995, 242:553-561.
11. Veinot J.P., Harrity P.J., Gentile F., et al. Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination. Circulation 1997, 96:3112-3115.
12. Sharma S., Devine W., Anderson R.H., et al. The determination of atrial arrangement by examination of appendage morphology in 1842 heart specimens. Br Heart J 1988, 60:227-231.
13. Raman R., Al-Ali S.Y., Poole C.A., et al. Isomerism of the right atrial appendages: clinical, anatomical, and microscopic study of a long-surviving case with asplenia and ciliary abnormalities. Clin Anat 2003, 16:269-276.
14. Friedberg M.K., Ursell P.C., Silverman N.H. Isomerism of the left atrial appendage associated with ventricular noncompaction. Am J Cardiol 2005, 96:985-990.
15. Lai W.W., Ravishankar C., Gross R.P., et al. Juxtaposition of the atrial appendages: a clinical series of 22 patients. Pediatr Cardiol 2001, 22:121-127.
16. Panagiotopoulos K., Toumanidis S., Saridakis N., et al. Left atrial and left atrial appendage functional abnormalities in patients with cardioembolic stroke in sinus rhythm and idiopathic atrial fibrillation. J Am Soc Echocardiogr 1998, 11:711-719.
17. Zimmerman M.B., Blaine E.H., Stricker E.M. Water intake in hypovolemic sheep: effects of crushing the left atrial appendage. Science 1981, 211:489-491.
18. Kappagoda C.T., Linden R.J., Scott E.M., et al. Atrial receptors and heart rate: the efferent pathway. J Physiol 1975, 249:581-590.
19. Massoudy P., Beblo S., Raschke P., et al. Influence of intact left atrial appendage on hemodynamic parameters of isolated guinea pig heart. Eur J Med Res 1998, 3:470-474.
20. Rodeheffer R.J., Naruse M., Atkinson J.B., et al. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation 1993, 88:364-371.
21. Inoue S., Murakami Y., Sano K., et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000, 6:92-96.
22. Igarashi Y., Kashimura K., Makiyama Y., et al. Left atrial appendage dysfunction in chronic nonvalvular atrial fibrillation is significantly associated with an elevated level of brain natriuretic peptide and a prothrombotic state. Jpn Circ J 2001, 65:788-792.
23. Mikael Kortz R.A., Delemarre B.J., van Dantzig J.M., et al. Left atrial appendage blood flow determined by transesophageal echocardiography in healthy subjects. Am J Cardiol 1993, 71:976-981.
24. Bilge M., Eryonucu B., Güler N., et al. Transesophageal echocardiography assessment of left atrial appendage function in untreated systemic hypertensive patients in sinus rhythm. J Am Soc Echocardiogr 2000, 13:271-276.
25. Bilge M., Güler N., Eryonucu B., et al. Effect of blood pressure reduction on abnormal left atrial appendage function in untreated systemic hypertensive patients with sinus rhythm. Angiology 2001, 52:621-626.
26. Hoit B.D., Gabel M. Influence of left ventricular dysfunction on the role of atrial contraction: an echocardiographic-hemodynamic study in dogs. J Am Coll Cardiol 2000, 36:1713-1719.
27. Ito T., Suwa M., Kobashi A., et al. Influence of altered loading conditions on left atrial appendage function in vivo. Am J Cardiol 1998, 81:1056-1059.
28. Shirani J., Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol 2000, 9:95-101.
29. Hatem S. Atrial fibrillation: the tip of the iceberg. Arch Mal Coeur Vaiss 2002, 95:827-832.
30. Lai L.P., Su M.J., Lin J.L., et al. Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 1999, 33:1231-1237.
31. Weiss S. Rheumatic heart disease. Am Heart J 1933, 9:45-52.
32. Hellerstein H.K., Sinaiko E., Dolgin M. Amputation of the canine atrial appendages. Proc Soc Exp Biol Med 1947, 66:337.
33. Belcher J.R., Somerville W. Systemic embolism and left auricular thrombosis in relation to mitral valvotomy. BMJ 1955, 2:1000-1003.
34. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996, 61:755-759.
35. Suetsugu M., Matsuzaki M., Toma Y., et al. Detection of mural thrombi and analysis of blood flow velocities in the left atrial appendage using transesophageal two-dimensional echocardiography and pulsed Doppler flowmetry. J Cardiol 1988, 18:385-394.
36. Chan S.K., Kannam J.P., Douglas P.S., et al. Multiplane transesophageal echocardiographic assessment of left atrial appendage anatomy and function. Am J Cardiol 1995, 76:528-530.
37. Manning W.J., Silverman D.I., Gordon S.P., et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993, 328:750-755.
38. Fatkin D., Kelly R.P., Feneley M.P. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994, 23:961-969.
39. Shah S.J., Bardo D.M., Sugeng L., et al. Real-time three-dimensional transesophageal echocardiography of the left atrial appendage: initial experience in the clinical setting. J Am Soc Echocardiogr 2008, 21:1362-1368.
40. Nakajima H., Seo Y., Ishizu T., et al. Analysis of the left atrial appendage by three-dimensional transesophageal echocardiography. Am J Cardiol 2010, 106:885-892.
41. Budge L.P., Shaffer K.M., Moorman J.R., et al. Analysis of in vivo left atrial appendage morphology in patients with atrial fibrillation: a direct comparison of transesophageal echocardiography, planar cardiac CT, and segmented three-dimensional cardiac CT. J Interv Card Electrophysiol 2008, 23:87-93.
42. Lacomis J.M., Goitein O., Deible C., et al. Dynamic multidimensional imaging of the human left atrial appendage. Europace 2007, 9:1134-1140.
43. Wang Y., Di Biase L., Horton R.P., et al. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J Cardiovasc Electrophysiol 2010, 21:973-982.
44. Mohrs O.K., Ruebesam D., Peters J. Images in cardiology. Computed tomography in a patient after percutaneous left atrial appendage transcatheter occlusion (PLAATO). Heart 2006, 92:486.
45. Heist E.K., Refaat M., Danik S.B., et al. Analysis of the left atrial appendage by magnetic resonance angiography in patients with atrial fibrillation. Heart Rhythm 2006, 3:1313-1318.
46. Ho I.C., Neuzil P., Mraz T., et al. Use of intracardiac echocardiography to guide implantation of a left atrial appendage occlusion device (PLAATO). Heart Rhythm 2007, 4:567-571.
47. Tay K.H., Lip G.Y., Lane D.A. Atrial fibrillation and stroke risk prevention in real-life clinical practice. Thromb Haemost 2009, 101:415-416.
48. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008, 39:1901-1910. Stroke Risk in Atrial Fibrillation Working Group.
49. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001, 285:2864-2870.
50. Onalan O., Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke 2007, 38:624-630.
51. Crandall M.A., Bradley D.J., Packer D.L., et al. Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc 2009, 84:643-662.
52. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
53. Karthikeyan G., Eikelboom J.W. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe?. Thromb Haemost 2010, 104:45-48.
54. Lip G.Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
55. Lip G.Y., Frison L., Halperin J.L., et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010, 41:2731-2738.
56. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med 1992, 327:1406-1412.
57. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991, 84:527-539.
58. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European atrial fibrillation trial) study group. Lancet 1993, 342:1255-1262.
59. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687-691.
60. Diener H.C. Antiplatelet agents and randomized trials. Rev Neurol Dis 2007, 4:177-183.
61. Petersen P., Boysen G., Godtfredsen J., et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989, 1:175-179.
62. Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
63. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006, 48:854-906.
64. Hylek E.M., Go A.S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026.
65. Hylek E.M., Skates S.J., Sheehan M.A., et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540-546.
66. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
67. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912.
68. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
69. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
70. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:546S-592S.
71. Wysowski D.K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167:1414-1419.
72. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993, 95:315-328.
73. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120:700-705.
74. Sudlow M., Thomson R., Thwaites B., et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998, 352:1167-1171.
75. Brass L.M., Krumholz H.M., Scinto J.M., et al. Warfarin use among patients with atrial fibrillation. Stroke 1997, 28:2382-2389.
76. Go A.S., Hylek E.M., Borowsky L.H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131:927-934.
77. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics subcommittee. Circulation 2009, 119:480-486.
78. White H.D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007, 167:239-245.
79. Healey J.S., Crystal E., Lamy A., et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005, 150:288-293.
80. Dawson A.G., Asopa S., Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?. Interact Cardiovasc Thorac Surg 2010, 10:306-311.
81. Kanderian A.S., Gillinov A.M., Pettersson G.B., et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008, 52:924-929.
82. Odell J.A., Blackshear J.L., Davies E., et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction?. Ann Thorac Surg 1996, 61:565-569.
83. Blackshear J.L., Johnson W.D., Odell J.A., et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol 2003, 42:1249-1252.
84. Salzberg S.P., Plass A., Emmert M.Y., et al. Left atrial appendage clip occlusion: early clinical results. J Thorac Cardiovasc Surg 2010, 139:1269-1274.
85. Ailawadi G., Gerdisch M.W., Harvey R.L., et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. J Thorac Cardiovasc Surg 2011, 142:1002-1009. 1009,e1.
86. Bruce C.J., Stanton C.M., Asirvatham S.J., et al. Percutaneous epicardial left atrial appendage closure: intermediate-term results. J Cardiovasc Electrophysiol 2011, 22:64-70.
87. Sievert H., Lesh M.D., Trepels T., et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002, 105:1887-1889.
88. Ostermayer S.H., Reisman M., Kramer P.H., et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005, 46:9-14.
89. Block P.C., Burstein S., Casale P.N., et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv 2009, 2:594-600.
90. Bayard Y.L., Omran H., Neuzil P., et al. PLAATO (percutaneous left atrial appendage transcatheter occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention 2010, 6:220-226.
91. Park J.W., Leithäuser B., Gerk U., et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-year outcomes. J Invasive Cardiol 2009, 21:446-450.
92. Fuller C.J., Reisman M. Stroke prevention in atrial fibrillation: atrial appendage closure. Curr Cardiol Rep 2011, 13:159-166.
93. Fountain R.B., Holmes D.R., Chandrasekaran K., et al. The protect AF (Watchman Left Atrial Appendage System for Embolic protection in Patients with Atrial Fibrillation) trial. Am Heart J 2006, 151:956-961.
94. Sick P.B., Schuler G., Hauptmann K.E., et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007, 49:1490-1495.
95. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374:534-542.
96. Reddy V.Y., Holmes D., Doshi S.K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in patients With Af (Protect Af) Clinical Trial and the Continued Access Registry. Circulation 2011, 123:417-424.
97. Meier B., Palacios I., Windecker S., et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003, 60:417-422.
98. Park J.W., Bethencourt A., Sievert H., et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011, 77:700-706.
99. Lam Y.Y., Yip G.W., Yu C.M., et al. Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv 2012, 79:794-800.
100. Bartus K., Bednarek J., Myc J., et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm 2011, 8:188-193.
101. Schwartz R.S., Holmes D.R., Van Tassel R.A., et al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. JACC Cardiovasc Interv 2010, 3:870-877.
102. Katz E.S., Tsiamtsiouris T., Applebaum R.M., et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol 2000, 36:468-471.